arrow
N

Nobumichi Tanaka

Nara Medical University
H指数:33
被引数:4,382

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC

在转移性CRPC中,达到CRPC前达到的最低PSA水平可预测阿比特龙的治疗反应,但不能预测恩扎卢amide的治疗反应

2026-09-290
PRE
Evaluating Risk Factors Associating With Late Recurrence After Low-Dose-Rate Brachytherapy for Prostate Cancer Using Machine Learning

利用机器学习评估低剂量率近距离放射治疗前列腺癌后晚期复发的风险因素

2026-09-290
PRE
FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer

FGFR3基因改变和蛋白质表达在配对TURBT和根治性膀胱切除术存档标本中的肌层浸润性膀胱癌

2026-09-290
OA
Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone

吸烟的转移性去势抵抗性前列腺癌患者接受恩扎卢替尼或阿比特龙治疗时,糖尿病或高血压的预后影响

2026-09-190
PRE
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa

恩扎卢替尼和阿比特龙在既往有其他癌症史的患者中的有效性和安全性:针对PCa的ENABLE研究的亚组分析

2026-05-201
PRE
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial

塞来昔布联合低剂量率近距离放射治疗对前列腺癌长期肿瘤学结局和生活质量的影响:一项开放标签对照随机试验的事后分析

2026-01-010
PRE
Clinical Utility of Ureteral Optical Coherence Tomography for T Staging of Ureteral Cancer: NOCTURN Study

输尿管光学相干断层扫描在输尿管癌T分期中的临床应用价值:NOCTURN研究

2025-10-010
PRE
Risk factors for early arteriovenous fistula failure in patients undergoing hemodialysis and comparison of diagnostic prediction models

血液透析患者早期动静脉瘘失败的危险因素及诊断预测模型的比较

2025-08-050
PRE
Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer

Nectin-4下调的临床意义以及细胞毒性化疗在膀胱癌中引起的生物学变化

2025-06-250
PRE
Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)
2024-02-015
PRE
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
2022-07-0110
OAAI